Literature DB >> 15265314

Cannabinoids in pain and inflammation.

Estery C Mbvundula1, K D Rainsford, Rowena A D Bunning.   

Abstract

Cannabinoids exhibit medicinal properties including analgesic, anti-inflammatory and immunosuppressive properties. This paper reviews some of the recent findings in the study of cannabinoids in pain and inflammation. Some of the effects of cannabinoids are receptor mediated and others are receptor independent. Endocannabinoids naturally reduce pain and are cerebroprotective. Natural and synthetic cannabinoids have the potential to reduce nociception, reverse the development of allodynia and hyperalgesia, reduce inflammation and inflammatory pain and protect from secondary tissue damage in traumatic head injury.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15265314     DOI: 10.1163/1568560041352275

Source DB:  PubMed          Journal:  Inflammopharmacology        ISSN: 0925-4692            Impact factor:   4.473


  15 in total

1.  Acute and chronic administration of the cannabinoid receptor agonist CP 55,940 attenuates tumor-evoked hyperalgesia.

Authors:  Darryl T Hamamoto; Subhalakshmi Giridharagopalan; Donald A Simone
Journal:  Eur J Pharmacol       Date:  2006-12-09       Impact factor: 4.432

Review 2.  In vivo imaging of the endocannabinoid system: a novel window to a central modulatory mechanism in humans.

Authors:  Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-11       Impact factor: 9.236

Review 3.  New Insights in Cannabinoid Receptor Structure and Signaling.

Authors:  Lingyan Ye; Zheng Cao; Weiwei Wang; Naiming Zhou
Journal:  Curr Mol Pharmacol       Date:  2019       Impact factor: 3.339

4.  Heteroadamantyl cannabinoids.

Authors:  Darryl D Dixon; Divakaramenon Sethumadhavan; Tore Benneche; April R Banaag; Marcus A Tius; Ganesh A Thakur; Anna Bowman; Jodianne T Wood; Alexandros Makriyannis
Journal:  J Med Chem       Date:  2010-08-12       Impact factor: 7.446

5.  Examining the critical roles of human CB2 receptor residues Valine 3.32 (113) and Leucine 5.41 (192) in ligand recognition and downstream signaling activities.

Authors:  Mohammed Alqarni; Kyaw Zeyar Myint; Qin Tong; Peng Yang; Patrick Bartlow; Lirong Wang; Rentian Feng; Xiang-Qun Xie
Journal:  Biochem Biophys Res Commun       Date:  2014-08-19       Impact factor: 3.575

6.  Rimonabant reduces keratinocyte viability by induction of apoptosis and exerts topical anti-inflammatory activity in mice.

Authors:  Anna Maria Malfitano; Silvio Sosa; Chiara Laezza; Marco De Bortoli; Aurelia Tubaro; Maurizio Bifulco
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

Review 7.  Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia.

Authors:  Armen N Akopian; Nikita B Ruparel; Nathaniel A Jeske; Amol Patwardhan; Kenneth M Hargreaves
Journal:  Trends Pharmacol Sci       Date:  2008-12-11       Impact factor: 14.819

8.  Cannabinoid modulation of cutaneous Adelta nociceptors during inflammation.

Authors:  Carl Potenzieri; Thaddeus S Brink; Cholawat Pacharinsak; Donald A Simone
Journal:  J Neurophysiol       Date:  2008-09-10       Impact factor: 2.714

9.  The cannabinoid receptor agonist, WIN 55, 212-2, attenuates tumor-evoked hyperalgesia through peripheral mechanisms.

Authors:  Carl Potenzieri; Catherine Harding-Rose; Donald A Simone
Journal:  Brain Res       Date:  2008-04-06       Impact factor: 3.252

10.  Differential modulation of nociceptive versus non-nociceptive synapses by endocannabinoids.

Authors:  Alexandra Higgins; Sharleen Yuan; Yanqing Wang; Brian D Burrell
Journal:  Mol Pain       Date:  2013-06-01       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.